LETTER
Correction: Misclassification of Clonidine
Ila V. Mehra, PharmD
15 February 1994 | Volume 120 Issue 4 | Page 347
TO THE EDITOR:
In their recent review of drug-induced disorders of glucose tolerance, Pandit and colleagues [1] state that clonidine is a centrally acting 
-blocker. However, this is an error. Clonidine is, in fact, classified as a selective -2 agonist. The blood pressure-lowering effects of clonidine result from activation of -2 receptors in the central nervous system, which reduces sympathetic outflow [2].
|
Author and Article Information
|
|---|
Medical University of South Carolina; Charleston, SC 29425
1. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993; 118: 529-39.
2. Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 8th edition. New York: McGraw-Hill; 1993:208-9.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
Author & Article Info
References
Article
